Caffeine 0.2% vs Minoxidil 5% for Male Pattern Hair Loss: Dhurat 2017 Research Summary
This is a plain-language summary of the original published research. We do not add conclusions or opinions of our own. This is not medical advice — consult a certified healthcare practitioner before making any decision.
Original research published in Skin Pharmacology and Physiology, 2017
Caffeine 0.2% vs Minoxidil 5% for Male Pattern Hair Loss
Study conclusion
Open-label RCT of 210 men found caffeine 0.2% topical was non-inferior to minoxidil 5% in anagen hair proportion at 6 months. Funded by Kurt Wolff GmbH (Alpecin maker). Open-label design and industry funding significantly limit conclusions.
Strength of evidence
This was an open-label RCT — participants knew which treatment they were using, making placebo effects impossible to control. The score is very limited because of industry funding by the Alpecin manufacturer and the open-label design. Non-inferiority trials also require careful interpretation — showing 'no worse than' is not the same as showing it works.
Who it applies to
Who was studied
210 men with pattern hair loss. Open-label design (not blinded). Caffeine-based 0.2% topical vs 5% minoxidil for 6 months.
Who was NOT studied
Women. Double-blind conditions. Long-term use beyond 6 months.
What to look for when shopping
The caffeine product tested was an Alpecin-specific formulation. Generic caffeine topicals may differ. Neither product type is FDA-approved for hair loss.
What research cannot help you decide
Whether caffeine topical truly performs as well as minoxidil in a double-blind placebo-controlled trial.
Key findings
- Caffeine 0.2% topical was non-inferior to minoxidil 5% in anagen hair proportion at 6 months
- Trial was open-label — participants knew which treatment they were receiving
- Trial was funded by Kurt Wolff GmbH, maker of Alpecin caffeine shampoo
- Non-inferiority means not significantly worse — not the same as equivalence to minoxidil in all hair outcomes
- Neither product is FDA-approved for hair loss
What they did
210 men with male pattern hair loss were randomly assigned to caffeine-based 0.2% topical solution or minoxidil 5% solution for 6 months. Neither participants nor investigators were blinded. The proportion of anagen hairs was measured as the primary outcome.
What they found
| Comparison | Result | Significant? |
|---|---|---|
| Caffeine 0.2% vs minoxidil 5% — anagen hair proportion at 6 months | Non-inferior (not significantly worse) | No |
| Caffeine 0.2% vs minoxidil 5% — hair count | Not reported as primary outcome | No |
What this study does not show
- 1.Whether caffeine topical would prove non-inferior in a double-blind placebo-controlled trial.
- 2.Whether caffeine topical is equivalent to minoxidil in overall hair count or density (this was not the primary outcome).
- 3.Whether results apply to other caffeine formulations beyond the Alpecin-specific product tested.
Limitations
- 1.Open-label design — participants knew which treatment they were receiving
- 2.Industry-funded by Kurt Wolff GmbH (maker of Alpecin)
- 3.Non-inferiority design: shows not worse rather than works independently vs placebo
- 4.Only 6 months of follow-up
- 5.Neither product is FDA-approved for hair loss
Who funded it
Funded by Kurt Wolff GmbH, manufacturer of Alpecin caffeine shampoo.
Used in these articles
Links added as fact-checks and articles citing this study are published.